Latest news for CSPC Pharma Gr (OTC:CHJTF) Stock

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC PHARM GROUP LTD ORD by CSPC Pharmaceuticals Group Ltd.

CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has renewed lease agreements with CHL and NCP for three years...

CSPC Pharmaceutical Group Secures New Lease Agreements

CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has received approval from China's National Medical Products ...

CSPC Pharmaceutical Gains Approval for Monthly Semaglutide Trials

CSPC Pharmaceutical Gains Approval for Cancer Drug Trials

CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group has announced the approval of clinical trials in China for it...

CSPC Pharmaceutical's New siRNA Drug Gets Clinical Trial Nod

CSPC Pharma Gains Approval for New Cancer Drug Trials

CSPC Pharmaceutical Group (HK:1093) has released an update. CSPC Pharmaceutical Group's breakthrough therapy, SYS6010, has been granted Breakthroug...

CSPC Pharmaceutical Gains Breakthrough Status for Cancer Therapy

An update from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group Limited announced that its SYH2059 Tablets have...

CSPC Pharmaceutical's SYH2059 Tablets Receive Clinical Trial Approval in China

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group Limited has announced the approval for clinical tria...

CSPC Pharma's SYS6045 Antibody-Drug Gets China Clinical Trial Nod

The latest announcement is out from CSPC Pharmaceutical Group ( ($HK:1093) ). CSPC Pharmaceutical Group has announced that its new product, SYS6041...

CSPC Pharmaceutical's SYS6041 Secures Clinical Trial Approval

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group has received marketing approval from China's Nationa...

Comments

CSPC Pharma Gr

News

Latest news for CSPC Pharma Gr (OTC:CHJTF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga